Hungarian Investment Promotion Agency

Having a history of more than 100 years, Egis is one of the leading pharmaceutical companies in Hungary and Central and Eastern Europe. The corporation owned by the French Servier Group sells its products in around 60 countries.

The Körmend site alone is responsible for manufacturing 100 million boxes of medicine per year that is equivalent to nearly 60% of Egis’ finished goods. The announced investment expands this capacity further, but that is just one of the benefits. The pill plant and the packaging plant will both be developed, whereas the production infrastructure of galenicals, i.e. non-solid forms of medicine such as creams, gels, solutions and the like will be also renewed. The establishment of new quality assurance laboratories is in the pipeline as well.

Built in 2019, the state-of-the-art galenical plant will be fitted with new modern machinery thanks to which production is to become more economical and efficient, and Egis can get existing popular products on the market with new packaging in accordance with changed market needs.

Part of the plan is also to set up analytics and microbiology labs that will support the activity of the finished product plant. These facilities can contribute to Egis’ effort to expand its oncology portfolio.